Cancer Biopsy Market Size & Share, By Product (Kits & Consumables, Instruments, Services), Type (Tissue Biopsies, Liquid Biopsies), Application, And Segment Forecasts, 2021 - 2027

Market Outlook:

Cancer Biopsy Market size surpassed USD 20.19 Billion in 2022 and is poised to reach USD 48.96 Billion, growing at over 12.79% CAGR between 2023 and 2030. The Market is driven by various factors such as technological advancements, increasing prevalence of cancer, and rising demand for personalized medicine.

• Base Year Value (2022): USD 20.19 Billion
• CAGR (2023-2030): 12.79%
• Forecast Year Value (2030): USD 48.96 Billion
• Historical Data Period: 2018-2021
• Largest Region: North America
• Forecast Period: 2023-2030

Market Dynamics:

Growth Drivers & Opportunities:

1. Technological Advancements: The continuous advancements in diagnostic technologies have revolutionized the cancer biopsy market. Techniques such as liquid biopsies, molecular diagnostics, and next-generation sequencing (NGS) have greatly improved the precision and accuracy of cancer detection, leading to increased adoption of biopsy procedures.

2. Increasing Prevalence of Cancer: The growing global burden of cancer has fueled the demand for diagnostic procedures like cancer biopsies. With the rise in the incidence of various types of cancers such as lung, breast, colorectal, and prostate, the need for efficient and reliable biopsy techniques has become paramount.

3. Rising Demand for Personalized Medicine: There has been a paradigm shift towards personalized medicine in cancer treatment, where therapies are tailored to individual patients based on genetic profiling. Cancer biopsies play a crucial role in identifying specific genetic mutations and biomarkers, aiding in the selection of targeted therapies, thereby driving the demand for biopsy procedures.

 

Industry Restraints & Challenges:

Report Scope

Report Coverage	Details
Segments Covered	Product, Type, Application, Region
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	QIAGEN, Illumina, ANGLE plc., BD, Myriad Genetics, Hologic, BIOCEPT, INC., Thermo Fisher Scientific, Danaher, F. Hoffmann-La Roche., Epigenomics AG, HelioHealth (Laboratory for Advanced Medicine), 20/20 Genesystems, (Genesys Biolabs), Personal Genome Diagnostics, Natera, Chronix Biomedical, Personalis, Lucence Health, Freenome Holdings, Grail, INC., Guardant Health, Exact Sciences, Biodesix (Integrated Diagnostics), Oncimmune

1. High Cost: Cancer biopsy procedures can be expensive, especially when advanced techniques and specialized tests are involved. The high cost of biopsy procedures can act as a deterrent for patients who may not have access to adequate healthcare coverage or resources.

2. Lack of Awareness: Despite the advancements in cancer diagnostics, there is a significant lack of awareness among individuals regarding the importance of early cancer detection and the role of biopsies in diagnosis. This lack of awareness hampers the uptake of biopsy procedures, leading to delayed or missed diagnoses.

3. Invasive Nature: Traditional biopsy procedures can be invasive, involving the use of needles or surgical instruments to extract tissue samples. This invasiveness may deter patients from undergoing the procedure, leading to missed opportunities for early detection and efficient treatment.

In conclusion, the cancer biopsy market is expected to witness continued growth in the coming years, driven by factors such as technological advancements, increasing prevalence of cancer, and the rise in demand for personalized medicine. However, challenges such as high costs, lack of awareness, and invasiveness of traditional biopsy procedures need to be addressed to ensure wider adoption and improved patient outcomes.

Regional Forecast:

North America:

In North America, the cancer biopsy market is expected to witness significant growth due to the increasing prevalence of cancer and the presence of a well-established healthcare infrastructure. Moreover, the growing adoption of advanced biopsy techniques and the availability of skilled healthcare professionals are further driving the market growth in this region.

Asia Pacific:

The Asia Pacific region is anticipated to experience rapid market growth during the forecast period. Factors such as the rising incidence of cancer, increasing awareness about early diagnosis, and advancements in healthcare infrastructure are contributing to the market expansion. Additionally, government initiatives promoting cancer screening programs are expected to boost market growth in this region.

Europe:

The European cancer biopsy market is projected to witness substantial growth owing to the growing geriatric population and the rising prevalence of cancer. Furthermore, supportive government initiatives, increased funding for cancer research, and the availability of technologically advanced biopsy tools are augmenting the market growth in Europe.

Segmentation Analysis:

Histology & Cytology:

Histology and cytology are integral sub-segments of the cancer biopsy market. In histology, tissue samples are obtained from the suspicious area for detailed cellular analysis. These samples are then examined by pathologists for the presence of cancer cells that help in accurate diagnosis. Cytology involves the collection and examination of individual cells to identify abnormal cellular changes. This two-pronged approach ensures effective cancer detection and aids in determining suitable treatment methods.

Immunohistochemistry:

Immunohistochemistry (IHC) is a crucial sub-segment of the cancer biopsy market. It involves the usage of antibodies tagged with fluorescent or color markers to detect specific proteins or antigens in the tumor cells. IHC aids in differentiating between various cancer types, determining the aggressiveness of tumors, and predicting the response to specific cancer therapies. The increasing use of IHC in diagnostic laboratories and research institutes has significantly contributed to the growth of this sub-segment.

Molecular Testing:

Molecular testing is another key sub-segment of the cancer biopsy market. It involves analyzing the genetic material or DNA alterations in cancer cells to identify specific mutations or biomarkers associated with different types of cancer. This enables personalized cancer treatment as it helps in selecting targeted therapies based on the individual's genetic profile. The demand for molecular testing is rising due to its ability to provide precise and accurate results, thus driving its market growth.

Competitive Landscape:

The cancer biopsy market is highly competitive, with several prominent players operating globally. These key market players strive to develop innovative and technologically advanced biopsy methods to enhance cancer detection accuracy and improve patient outcomes. Some of the leading companies in the market include Roche Diagnostics, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, and Abbott Laboratories. These companies focus on strategic collaborations, product launches, and mergers and acquisitions to strengthen their market position and expand their product portfolio.